<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856505</url>
  </required_header>
  <id_info>
    <org_study_id>00557</org_study_id>
    <nct_id>NCT00856505</nct_id>
  </id_info>
  <brief_title>Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Everolimus and Mycophenolate Sodium as GvHD Prophylaxis in Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In stem cell transplantation as treatment for malignant diseases, calcineurin inhibitors like&#xD;
      cyclosporine A are commonly used to prevent tissue destruction (GvHD) by activated donor&#xD;
      immune cells. The hypothesis for this study is, that replacing calcineurin inhibitors by&#xD;
      everolimus and mycophenolate as GvHD prophylaxis not only reduces toxicity of the treatment&#xD;
      but also improves tolerance induction of the donor T cells toward the host, eventually&#xD;
      increasing the safety of stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity according to CTCAE v3.0</measure>
    <time_frame>after 100 days and one year after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic engraftment</measure>
    <time_frame>day 30 after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GvHD</measure>
    <time_frame>one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Day 100 and one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>day 100 and one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Everolimus and mycophenolate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of experimental immunosuppressants for GvHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus and mycophenolate sodium</intervention_name>
    <description>Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident</description>
    <arm_group_label>Everolimus and mycophenolate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of hematologic malignancies, indicated for allogeneic stem cell&#xD;
             transplantation:&#xD;
&#xD;
          -  acute myeloid leukemia (AML), in CR1, ≥ CR2, primary refractory, relapse&#xD;
&#xD;
          -  chronic myeloid leukemia (CML), in chronic phase, in acceleration or blast crisis&#xD;
&#xD;
          -  myelodysplastic syndrome (MDS), RA/RARS (transfusion dependent), RAEB, RAEB-t and CMML&#xD;
&#xD;
          -  Lymphoma:&#xD;
&#xD;
               -  plasmocytoma&#xD;
&#xD;
               -  immunocytoma (M. Waldenström)&#xD;
&#xD;
               -  chronic-lymphatic leukemia (CLL)&#xD;
&#xD;
               -  additional low and high grade Non-Hodgkin Lymphoma&#xD;
&#xD;
          -  Hodgkins disease&#xD;
&#xD;
          -  HLA-matched (HLA-A, -B, -DRB1) related or unrelated donor available&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS involvement by underlying disease&#xD;
&#xD;
          -  Pulmonary disease with VC &lt; 55%, DLCO &lt; 40%&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 30%, uncontrollable arrhythmia&#xD;
&#xD;
          -  Creatinin &gt; 1,5 mg/dl or Creatinin-Clearance &lt; 30 ml/min&#xD;
&#xD;
          -  Bilirubin &gt; 2 mg/dl&#xD;
&#xD;
          -  Active Hepatitis B or C&#xD;
&#xD;
          -  HIV serologic positive&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Pre-menstrual women without medical safe contraception&#xD;
&#xD;
          -  Participation on another clinical trial in between 30 days before start or during the&#xD;
             study only if the clinical trial interferes with the outcome measures.&#xD;
&#xD;
          -  Known allergy to study medication or ingredients of the formulation&#xD;
&#xD;
          -  Drug- or alcohol abuse&#xD;
&#xD;
          -  Non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Finke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Freiburg, Div. Hematology/Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard Marks, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Freiburg, Div. Hematology/Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Marks, MD</last_name>
    <phone>49-761-270-</phone>
    <phone_ext>3278</phone_ext>
    <email>reinhard.marks@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juergen Finke, MD</last_name>
    <phone>49-761-270-</phone>
    <phone_ext>3408</phone_ext>
    <email>juergen.finke@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center, Division Hematology/Oncology</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Marks, MD</last_name>
      <phone>49-761-270</phone>
      <phone_ext>3278</phone_ext>
      <email>reinhard.marks@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Reinhard Marks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Finke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <last_update_submitted>March 4, 2009</last_update_submitted>
  <last_update_submitted_qc>March 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Jürgen Finke</name_title>
    <organization>University Hospital Freiburg</organization>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

